Tevogen Eyes HRK Healthcare in Potential Acquisition Shake-Up

Tevogen Inc. (Nasdaq: TVGN), an integrated healthcare enterprise combining biopharma, artificial intelligence, and healthcare services, announced on October 8, 2026, that it has entered into a signed, non-exclusive, non-binding Letter of Intent (LoI) to evaluate a potential transaction with HRK Healthcare LLC. The announcement, made from Tevogen's headquarters in Warren, New Jersey, marks a significant step in the company's strategy to expand its healthcare services footprint.

The LoI is non-binding and non-exclusive, meaning that both parties are free to explore other opportunities while conducting due diligence. Tevogen, which aims to improve the affordability and accessibility of life-saving medicines, has not disclosed the financial terms or a timeline for the evaluation. HRK Healthcare LLC's specific operations and assets remain unclear, but the potential acquisition aligns with Tevogen's mission to integrate biopharma, AI, and healthcare services. No official quotes were provided in the initial announcement.

If the acquisition proceeds, it could enhance Tevogen's service offerings and market position, though the non-binding nature of the agreement means there is no guarantee of a deal. Investors and industry watchers will be monitoring for further updates, including due diligence outcomes and any regulatory approvals. The global healthcare sector is increasingly consolidating, and this move reflects a broader trend of biopharma companies diversifying into healthcare services to drive synergies and improve patient access.